Parkinson’s Disease

Little Evidence Supports CSF α-Synuclein as a Diagnostic Tool for Parkinson Disease

Little Evidence Supports CSF α-Synuclein as a Diagnostic Tool for Parkinson Disease

By

The diagnosis of Parkinson disease is made mostly through a clinical assessment of motor signs and symptoms, which appear when approximately 70% of nigral neurons are lost.

Compulsive Behavior Disorders Common in Patients With Parkinson Disease With Dyskinesia

Compulsive Behavior Disorders Common in Patients With Parkinson Disease With Dyskinesia

By

Patients with dyskinesia had a significantly higher frequency of impulse control disorders.

MRI in Parkinson Disease: Expanding Usability for Better Diagnostics

MRI in Parkinson Disease: Expanding Usability for Better Diagnostics

By

MRI may be used to identify Parkinson disease biomarkers that can inform diagnosis, track disease progression, and elucidate the neurobiological underpinnings of symptoms.

Increased Mortality in Parkinson's Disease Linked to Low Antidepressant Adherence

Increased Mortality in Parkinson's Disease Linked to Low Antidepressant Adherence

By

Given the prevalence of depression in Parkinson's disease and the effectiveness of antidepressants, health care providers should promote adherence in clinical practice.

Parkinson's, ALS Risk Increased in White-Collar Workers

Parkinson's, ALS Risk Increased in White-Collar Workers

There is a higher risk of death from Parkinson's disease or ALS in white collar workers.

Several Factors May Predict Cognitive Decline in Parkinson's Disease

Several Factors May Predict Cognitive Decline in Parkinson's Disease

By

Dopamine deficiency, decreases in cortical thickness and volume in certain areas of the brain was predictive of cognitive decline.

Extended-Release Amantadine Reduces Levodopa-Induced Dyskinesia in Parkinson's Disease

Extended-Release Amantadine Reduces Levodopa-Induced Dyskinesia in Parkinson's Disease

By

Patients in the treatment group had improved ON and OFF times and no worsening of motor function.

Risk for Death Significantly Increased in Patients With Synucleinopathies

Risk for Death Significantly Increased in Patients With Synucleinopathies

By

Patients with multiple system atrophy with parkinsonism face the greatest risk for death among synucleinopathies.

No Link Between Parkinson's, Overall Vagotomy

No Link Between Parkinson's, Overall Vagotomy

However, there is a trend toward lower risk of Parkinson's for patients with truncal vagotomy.

Parkinson-Related Dyskinesia May Respond to Dextromethorphan, Quinidine Combo

Parkinson-Related Dyskinesia May Respond to Dextromethorphan, Quinidine Combo

By

Dextromethorphan is thought to have an impact on all 3 therapeutic pathways for dyskinesia.

An Interdisciplinary Approach to Advanced Parkinson's Care

An Interdisciplinary Approach to Advanced Parkinson's Care

Jori Fleisher, MD, MSCE, of New York University School of Medicine, discusses her research on an interdisciplinary home visit program for patients with advanced Parkinson's disease. Scroll below the video for the full transcript.

Impulse Control Disorders in Parkinson's Disease: Building Physician, Patient Awareness

Impulse Control Disorders in Parkinson's Disease: Building Physician, Patient Awareness

By

A patient should be notified of the possibility of developing an ICD before initiating any dopaminergic treatment for PD, particularly dopamine agonists.

Parkinson's Disease Off Time Reduced With Apomorphine

Parkinson's Disease Off Time Reduced With Apomorphine

By

A 150-year-old drug, apomorphine, may reduce off time in patients with Parkinson's disease.

Sign Up for Free e-newsletters

CME Focus